Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis

Huang, Jing-Juan; Ye, Sihua; Feng, Shaolan; Zheng, Minqi; Zhong, Meihua

doi:10.1007/s00384-023-04345-5

Cited by 3 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HFS prevalence in our study (all grades, 50.1%; grade ≥ 2, 14.6%) is consistent with previous ndings in other populations [7,9,10]. Despite urea cream being routinely prescribed for HFS at our centre and pharmacist counselling given, we still observed around 30% of the HFS cases worsened, and 20% required capecitabine treatment adjustments.…”

Section: Discussionsupporting

confidence: 91%

“…Moreover, 6% of them developed severe HFS. [10]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [10].…”

Section: Introductionmentioning

confidence: 81%

“…[10]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [10]. However, to our knowledge, no study has reported the HFS prevalence in the Malaysian population.…”

Section: Introductionmentioning

confidence: 82%

See 2 more Smart Citations

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

King,

Voon,

Yuen

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction Hand-foot syndrome (HFS) significantly impacts the quality of life in cancer patients undergoing capecitabine treatment. This study assessed capecitabine-associated HFS prevalence, its impacts on chemotherapy treatment, and identified risk factors in multiracial Malaysian patients. Methods We included adult cancer patients receiving capecitabine at Sarawak General Hospital for at least two cycles from April 1, 2021 to June 30, 2022. HFS rates, time to HFS, and proportions of HFS-related treatment modifications were determined. Characteristics between patients with and without HFS were compared and multivariable logistic regression was used to identify risk factors for all-grade HFS and grade ≥ 2. Results Among 369 patients, 185 (50.1%) developed HFS, with 14.6% experiencing grade ≥ 2. Notably, 21.6% of HFS cases underwent treatment modifications. Risk factors for all-grade HFS include older age (OR 1.04 95%CI 1.01, 1.06), prior chemotherapy (OR 2.12 95%CI 1.24, 3.61), higher capecitabine dose (OR 2.89 95%CI 1.69, 5.22), prolonged treatment (OR 1.34 95%CI 1.20, 1.49), and lower neutrophil count (OR 0.77 95%CI 0.66, 0.89). For HFS grade ≥ 2, older age (OR 1.04 95%CI 1.01, 1.08), female sex (OR 2.09 95%CI 1.05, 4.16), Chinese race (OR 2.07 95%CI 1.04, 4.10), and higher capecitabine dose (OR 2.61 95%CI 1.28, 5.32) are significant risk factors. Use of calcium channel blockers (OR 0.29, 95%CI 0.14, 0.59; OR 0.22 95%CI 0.66, 0.78) were associated with reduced risks of all-grade HFS and grade ≥ 2. Conclusion This study provides real-world data on capecitabine-induced HFS in Malaysian patients and identifies risk factors that may offer insights into its understanding and management.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 81%

See 1 more Smart Citation

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

King,

Voon,

Yuen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Moreover, 6% of them developed severe HFS. [ 11 ]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…[ 11 ]. The study also highlighted disparities in HFS prevalence across different countries, with China having the highest rate at 55.1%, followed by Japan, Korea, and Italy [ 11 ]. However, to our knowledge, no study has reported the HFS prevalence in the Malaysian population.…”

Section: Introductionmentioning

confidence: 99%

Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia

King,

Voon,

Yuen

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Introduction Hand-foot syndrome (HFS) significantly impacts quality of life in cancer patients undergoing capecitabine treatment. This study assessed capecitabine-associated HFS prevalence, its impacts on chemotherapy treatment, and identified risk factors in multiracial Malaysian patients. Methods We included adult cancer patients receiving capecitabine at Sarawak General Hospital for at least two cycles from April 1, 2021 to June 30, 2022. HFS rates, time to HFS, and proportions of HFS-related treatment modifications were determined. Characteristics between patients with and without HFS were compared and multivariable logistic regression was used to identify risk factors for all-grade HFS and grade ≥2. Results Among 369 patients, 185 (50.1%) developed HFS, with 14.6% experiencing grade ≥2 and 21.6% (40/185) underwent treatment modifications. Risk factors for all-grade HFS include older age (OR 1.03 95%CI 1.01, 1.06), prior chemotherapy (OR 2.09 95%CI 1.22, 3.58), higher capecitabine dose (OR 2.96 95%CI 1.62, 5.38), prolonged treatment (OR 1.36 95%CI 1.21, 1.51), folic acid intake (OR 3.27 95%CI 1.45, 7.35) and lower neutrophil count (OR 0.77 95%CI 0.66, 0.89). For HFS grade ≥2, older age (OR 1.04 95%CI 1.01, 1.08), female sex (OR 2.10 95%CI 1.05, 4.18), Chinese race (OR 2.10 95%CI 1.06, 4.18), and higher capecitabine dose (OR 2.62 95%CI 1.28, 5.35) are significant risk factors. Use of calcium channel blockers were associated with reduced risks of all-grade HFS (OR 0.27, 95%CI 0.12, 0.60) and grade ≥2 (OR 0.21 95%CI 0.06, 0.78). Conclusion This study provides real-world data on capecitabine-induced HFS in Malaysian patients and identifies risk factors that may offer insights into its understanding and management.

show abstract

Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens

Abdul Kareem,

Joseph,

Wilson

et al. 2024

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Hand-foot syndrome is a common adverse effect of 5-fluorouracil infusion or oral capecitabine. Several types of research have shown that clinical presentations of hand-foot syndrome vary by ethnicity, so we tried to look at the incidence and severity of hand-foot syndrome in individuals receiving infusional 5-fluorouracil or oral capecitabine at a tertiary care hospital in central Kerala, India. Aim To determine the incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine chemotherapy regimen. Methodology A prospective cohort study was conducted at the oncology department of a tertiary care hospital in Kerala, India. Our study subjects were those who underwent chemotherapy with infusional 5-fluorouracil or oral capecitabine and later developed hand-foot syndrome. The patients who developed hand-foot syndrome after chemotherapy were assessed to determine the incidence of hand-foot syndrome. Also, the severity of hand-foot syndrome among cancer patients was estimated using CTCAE version 5.0. Results Out of 104 study participants, 76.90% ( N = 80) of the patients had hand-foot syndrome, whereas 23.07% ( N = 24) did not. The onset of hand-foot syndrome symptoms varied depending on the patient. Most patients (60%) displayed grade-one symptoms in their third cycle. The remaining patients showed grade-one symptoms in cycle one (3.75%), cycle two (17.5%), and cycle four (18.75%). The study also showed t no association between the incidence of hand-foot syndrome and the type of regimen. Conclusion The majority of the patients suffered from hand-foot syndrome. As well, most of the patients were afflicted by grade one hand-foot syndrome.

show abstract

Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis

Cited by 3 publications

References 40 publications

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in Malaysia

Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia

Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens

Contact Info

Product

Resources

About